About Cidqo
Cidqo is a company based in Barcelona (Spain) founded in 2012 was acquired by Suanfarma in March 2013. Cidqo offers products and services including Organic Synthesis, Analytical Chemistry, Intellectual Property Evaluation, and Quality Assurance. Cidqo operates in a competitive market with competitors including GSK, Avidity Biosciences, Sutro Biopharma, Antheia and Vividion Therapeutics, among others.
- Headquarter Barcelona, Spain
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
- Legal Name Cidqo 2012, Sl
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Cidqo
Cidqo offers a comprehensive portfolio of products and services, including Organic Synthesis, Analytical Chemistry, Intellectual Property Evaluation, and Quality Assurance.
Designs synthetic routes for APIs and intermediates.
Develops and validates methods for HPLC and spectroscopy.
Evaluates patents and innovative chemical routes.
Provides regulatory support and process optimization.
Funding Insights of Cidqo
Investors in Cidqo
Cidqo has secured backing from 3 investors, including venture fund and institutional investors. Prominent investors backing the company include Suanfarma, European Union and EIC Fund.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Government agency and accelerator focusing on innovative startups and SMEs
|
Locked | Locked | Locked | |
|
Government entites focused on freedom, democracy, equality and the rule of law, promoting peace and stability
|
Locked | Locked | Locked | |
|
Generics, nutraceuticals, and APIs are developed by Suanfarma.
|
Locked | Locked | Locked |
Investor details for Cidqo
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Cidqo
Investment portfolio details for Cidqo
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Cidqo
Detailed financials for Cidqo
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Cidqo Comparisons
Peer comparison for Cidqo
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Cidqo
Cidqo operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as GSK, Avidity Biosciences, Sutro Biopharma, Antheia and Vividion Therapeutics, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Developer of pharmaceuticals and vaccines for various therapeutic areas
|
|
| Locked | Locked | Locked |
Antibody-siRNA complexes are developed for cancer treatment.
|
|
| Locked | Locked | Locked |
Antibody-based therapeutics for cancer therapy are developed via cell-free synthesis.
|
|
| Locked | Locked | Locked |
Yeast cells are genetically engineered to produce medicinal products.
|
|
| Locked | Locked | Locked |
Developing novel drugs based on a proteome-wide ligand and target discovery platform
|
|
| Locked | Locked | Locked |
CRISPR-engineered cell and gene therapies are developed for research applications.
|
Detailed competitors of Cidqo
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Cidqo
Complete news archive for Cidqo
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Cidqo
Cidqo was founded in 2012 and raised its 1st funding round 3 years after it was founded.
Cidqo is headquartered in Barcelona, Spain. It is registered at Barcelona, Catalonia, Spain.
Cidqo was established in 2012 in Barcelona, Spain, within the pharmaceuticals sector. Combinatorial chemistry is employed for developing active pharmaceutical ingredients and intermediates. Services in API production are provided, with completed developments including N-Acetyl Cysteine (NAC), L-Carnosine, Dapoxetine, Tenofovir, Rivastigmine, and Diacerein. Ongoing efforts focus on Cinacalcet HCL, Adenine, and Emtricitabine.
Cidqo's top competitors include Sutro Biopharma, Synthego and Avidity Biosciences.
Cidqo offers Organic Synthesis, Analytical Chemistry, Intellectual Property Evaluation, and Quality Assurance.
Cidqo has 3 investors. Key investors include Suanfarma, European Union, and EIC Fund.